

- for brain metastases, 1792
- for CAH, 334, 2329
- for cerebral edema, 598
- drug interactions of, 246e-3t
- for enteric fever, 1052
- for fatigue, 63
- for hypoadrenal shock, 1751
- for increased intracranial pressure, 1780t
- for meningitis, 780t, 889, 890, 1011
- for multiple myeloma, 716-717
- for nausea and vomiting, 62, 103e-25, 474
- for neurocysticercosis, 903
- for pain, 61
- as premedication for taxanes, 103e-15
- for prenatal treatment of CAH, 2356
- for spinal cord compression, 2653
- for tuberculous meningitis, 899
- Dexamethasone suppression test, 332, 415e-4, 2310
- Dexlansoprazole, 263, 1920, 1920t
- Dexmedetomidine, 1782
- Dexrazoxane, 103e-13, 621
- Dextroamphetamine, 61, 63, 190
- Dextrocardia, 269e-16f, 1528
- Dextromethorphan, 245, 473e-13t
- Dextrose, 298, 304, 312
- DF (discriminant function) value, 2059
- DGM (diphosphoglycerate mutase) deficiency, 654t
- DHCR7* gene mutations, 2354t
- DHEA. *See* Dehydroepiandrosterone (DHEA)
- DHF (dihydrofolate) reductase, 641, 642f, 931t, 934
- DHF (dihydrofolate) reductase inhibitors, 246e-4t, 246e-12
- DHH* gene mutations, 2354t
- Dhori virus, 1310t
- DHPR (dihydropteridine reductase) deficiency, 434e-2t
- DHT (dihydrotestosterone), 332, 2358, 2359f. *See also* Testosterone
- Diabetes insipidus (DI), **2275**
 - adipsic, 304
 - differential diagnosis of, 2277-2278, 2278f
 - etiology of, 2275-2276, 2277t
 - gestational, 303, 2276
 - nephrogenic
 - clinical features of, 64e-3, 294-295, 303
 - diagnosis of, 294f, 304
 - early interventions for, 450t
 - etiology of, 294f, 295, 297, 303, 2276, 2277t
 - genetic considerations in, 332e-7t
 - genetic testing for, 450t
 - lithium-associated, 64e-3-4
 - pathogenesis of, 303
 - treatment of, 64e-4, 304
 - pathophysiology of, 2276-2277
 - pituitary (central, neurohypophyseal)
 - clinical features of, 294-295, 303
 - diagnosis of, 294f, 304
 - early interventions for, 450t
 - etiology of, 294f, 295, 297, 2277t
 - genetic considerations in, 435
 - genetic forms of, 2276, 2277t
 - genetic testing for, 450t
 - treatment of, 304
 - treatment of, 2278-2279, 2279f
- Diabetes mellitus (DM), **2399**
 - abdominal pain in, 106, 106t
 - anemia in, 398
 - approach to the patient, 2406-2407
 - celiac disease and, 1942
 - classification of, 2399-2400, 2399f, 2399t, 2407
 - complications of, **2422**, 2422t
 - cardiovascular. *See* Cardiovascular disease, in diabetes mellitus
 - cutaneous, 2429-2430
 - detection and prevention of, 2408, 2408t
 - diabetic ketoacidosis. *See* Diabetic ketoacidosis (DKA)
 - dyslipidemia, 2428
 - erectile dysfunction, 326, 2427
 - female sexual dysfunction, 330, 2427
 - gastrointestinal, 258, 2427
 - genitourinary, 862, 2427
 - glycemic control and, 2422-2423, 2423f
 - hyperglycemic hypermolar state, 2417, 2417t, 2420
 - hyperkalemia, 309
 - hypertension, 2428
 - hypoglycemia. *See* Hypoglycemia, in diabetes mellitus
 - infections, 2429
 - lactic acidosis, 318
 - lower extremity
 - osteomyelitis, 845, 845f
 - pathophysiology of, 839, 2428
 - prevention of, 2428-2429
 - treatment of, 477e-4t, 2429
 - mechanisms of, 2423-2424
 - neuromuscular involvement, 462e-19
 - neuropathy. *See* Diabetic neuropathy
 - ocular
 - abducens nerve palsy, 209
 - cataracts, 204
 - epiretinal membrane, 206
 - retinopathy. *See* Diabetic retinopathy
 - tonic pupil, 196
 - vitreous degeneration, 204
 - renal. *See* Diabetic nephropathy
 - retinopathy. *See* Diabetic retinopathy
 - contrast agent risk in, 1461, 2425
 - cystic fibrosis-related, 1697
 - deaths from, 6e-1t, 56t
 - definition of, 2399
 - depression in, 2714
 - in developing countries, 15, 266e-4
 - diagnosis of, 2401, 2401f, 2401t
 - diarrhea in, 270, 272, 855t
 - in elderly, 82
 - epidemiology of, 2400
 - erythropoietin deficiency in, 398
 - etiology of, 2399-2400, 2400t
 - frailty and, 77, 82
 - fulminant, 2400
 - genetic considerations in, 431t, 441, 441t, **2404**
 - gestational, 6e-3-4, 48, 2400, 2422
 - global considerations in, 15, 266e-4, 2400, 2400f
 - gut microbiota and, 86e-8-9
 - HCV infection and, 2041
 - in hemochromatosis, 2516
 - high-altitude travel and, 476e-5
 - history in, 2406
 - immunization recommendations for, 788f
 - incidence of, 2400
 - in Kearns-Sayre syndrome, 462e-15
 - latent autoimmune in the adult, 2407
 - lipodystrophic, 2422
 - maturity-onset of the young (MODY), 431t, 441t, 2400, 2406
 - nausea and vomiting in, 258
 - obstructive sleep apnea and, 1724
 - oral manifestations of, 236
 - otitis externa in, 228-229
 - pancreatic cancer and, 554
 - parenteral nutrition in patient with, 98e-7, 2421
 - physical examination in, 2406-2407
 - polyuria in, 295
 - in pregnancy, 47-48
 - preoperative evaluation and management of, 55
 - prevalence of, 2400, 2400f
 - prevention of, 17
 - screening for, 29t, 84, 2401t, 2402
 - skin manifestations of, 359, 361t, 362, 363, 365, 436e-4f, 2429-2430
 - stroke risk in, 2567t
 - systems biology applied to, 87e-3t
 - taste disorders in, 215
 - treatment and management of, **2407**
 - blood glucose monitoring in, 2409-2410
 - complication detection and prevention, 2408, 2408t
 - in elderly, 82
 - emerging therapies, 2417
 - exercise, 2408
 - during glucocorticoid therapy, 2421-2422
 - glycemic control monitoring, 2410
 - glycemic control targets, 2410
 - goals and principles of, 2407-2408, 2408t
 - in hospitalized patients, 2420-2421
 - medical nutrition therapy in, 2408-2409, 2409t
 - multidisciplinary team in, 2407-2408
 - ongoing aspects of, 2407-2408, 2408t
 - outpatient, improvement of, 12e-3
 - during parenteral nutrition therapy, 2421
 - patient education in, 2408-2409
 - in pregnancy, 2422. *See also* Gestational diabetes mellitus
 - stem cell therapy for, 90e-2-3
 - type 1, **2403**
 - APS-1 and, 2346t
 - APS-2 and, 2346, 2347t
 - environmental factors in, 2404
 - genetic considerations in, 2403
 - HLA gene association with, 373e-8, 373e-8t
 - hypertension management, 2426
 - immunologic markers in, 2404
 - immunopathogenesis of, 372e-24t, 372e-27t, 372e-28, 2403, 2403f
 - inflammatory mediators in, 372e-29t
 - KIRs with, 372e-15t
 - pathophysiology of, 2403-2404
 - prevention of, 2404
 - treatment and management of, **2410**
 - adverse effects of, 2417
 - emerging therapies, 2417
 - goals of, 2408t, 2410-2411
 - insulin preparations, 2411, 2411t
 - insulin regimens, 2411-2412, 2412f
 - intensive management, 2411
 - pramlintide, 2412-2413
 - type 2, **2404**
 - bariatric surgery and, 2398
 - genetic considerations in, 440-441, 441t, 2404
 - hypertension management, 2426
 - insulin resistance syndromes in, 2405-2406
 - ketosis-prone, 2407
 - metabolic abnormalities in, 2404-2405, 2405f
 - metabolic syndrome and, 291e-6-7, 2450, 2452
 - obesity and, 415e-6
 - pathophysiology of, 2404, 2405f
 - postmenopausal hormone therapy and, 2384t
 - prevalence of, 2254t
 - prevention of, 2406
 - risk factors for, 2401, 2401t
 - in schizophrenia, 2722
 - screening/testing for, 2254t
 - treatment and management of, **2413**, 2413f, 2414t
 - adverse effects of, 2417
 - α -glucosidase inhibitors, 2415
 - biguanides, 2413
 - bile acid-binding resins, 2415
 - bromocriptine, 2415
 - combination therapy, 2416-2417
 - emerging therapies, 2417
 - insulin secretagogues, 2413-2415
 - insulin therapy, 2415-2416
 - selection of initial agents, 2416, 2416f
 - sodium-glucose co-transporter 2 inhibitors, 2415
 - thiazolidinediones, 2415
 - in women, 6e-2f, 6e-3-4
 - Diabetic diarrhea, 270, 272, 855t, 1942
 - Diabetic ketoacidosis (DKA), **2418**
 - clinical features of, 2418, 2418t
 - complications of, 2420
 - diagnosis of, 64e-1, 2418, 2418t
 - hypokalemia in, 305
 - hyponatremia in, 299
 - pathophysiology of, 318, 2418, 2418t